Treatment of pervasive developmental disorders with redox-active therapeutics
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
1. A method of reducing one or more symptoms associated with, or of treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD) in a patient in need thereof, comprising administering to the patient a therapeutically or physiologically effective amount of one or more compounds of Formula II,
wherein,
the bonds indicated with a dashed line are independently single bonds or double bonds; and
R 1 , R 2 , and R 3 are independently selected from the group consisting of H, (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, halogen and CN;
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
2. The method according to claim 1 , comprising administering a therapeutically or physiologically effective amount of one or more compounds of Formula IIa,
or a stereoisomer, a mixture of stereoisomers, a solvate or a hydrate thereof.
3. The method according to claim 1 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing a Pervasive Developmental Disorder (PDD).
4. The method according to claim 2 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing a Pervasive Developmental Disorder (PDD).
5. The method according to claim 1 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).
6. The method according to claim 2 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).
7. The method of claim 1 , where the bonds indicated with a dashed line are all double bonds.
8. The method of claim 1 , where the bonds indicated with a dashed line are all single bonds.
9. The method of claim 2 , where the bonds indicated with a dashed line are all double bonds.
10. The method of claim 2 , where the bonds indicated with a dashed line are all single bonds.
11. The method of claim 1 , wherein R 1 , R 2 , and R 3 are independently (C 1 -C 4 )alkyl.
12. The method of claim 1 , wherein R 1 and R 2 are independently (C 1 -C 4 )alkoxy, and R 3 is (C 1 -C 4 )alkyl.
13. The method of claim 9 , wherein the one or more compounds are administered in the form of liposomes.
14. The method of claim 9 , wherein the one or more compounds are administered in a medical food, functional food, food supplement, or dietary supplement.
15. The method according to claim 2 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing Rett syndrome.
16. The method according to claim 2 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing autism.
17. The method according to claim 9 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing a Pervasive Developmental Disorder (PDD).
18. The method according to claim 9 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing attention deficit/hyperactivity disorder (ADHD).
19. The method according to claim 9 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing autism.
20. The method according to claim 9 , wherein the method is for reducing one or more symptoms associated with, or for treating or suppressing Rett syndrome.